Obama Administration Unveils Bioeconomy Blueprint, Calls for Acceleration of Non-Embryonic Stem Cell Research for Treatment of Blood Diseases
Published on: May 01, 2012
Specifically, one of the commitments states
that the NIH Center for Regenerative Medicine and its partners are exploring
the development of induced pluripotent stem (iPS) cell therapies to treat blood-related
diseases such as leukemia and that the researchers will investigate whether iPS
cells can be used to develop blood products that could help meet the demand for
blood transfusions during medical emergencies and surgeries. Please see
page 18 of the Bioeconomy Blueprint and page 2 of the
commitments document for more information.
Blueprint and the federal agency commitments that will help implement it are
consistent with the ASH
Agenda for Hematology Research, a strategic plan that the Society
recently released, which identifies the most promising areas of research that
require ongoing support.